Filament

Far Eastern New Century aims for zero waste and low carbon emission through circular economy

Retrieved on: 
Wednesday, October 19, 2022
The Economist, Aviation biofuel, FENC, Life, Hygiene, Filament, Carbon, FIFA, Recycling, Parley, Multimedia, Technology, Economics of the FIFA World Cup, Food, PET, Adidas, Industrial waste, USD, Renewable energy

FENC integrated multiple resources and environmentally friendly products from FENC vertical chain, developing high performance functional and sustainable fabrics for international brands.

Key Points: 
  • FENC integrated multiple resources and environmentally friendly products from FENC vertical chain, developing high performance functional and sustainable fabrics for international brands.
  • Not only satisfy the everyday wear of end consumers, FENC also had been a major supplier at global sporting events.
  • The fabrics scraps and used clothes with go through a process of sorting, shredding, melting, pelletizing and spinning.
  • FENC TOPGREEN Bio3 PET utilizes LanzaTech CCU technology that transforms industrial waste gas into low carbon ethylene glycol (EG), which then turn into brand new polyester.

Far Eastern New Century aims for zero waste and low carbon emission through circular economy

Retrieved on: 
Wednesday, October 19, 2022
The Economist, Aviation biofuel, FENC, Life, Hygiene, Filament, Carbon, FIFA, Recycling, Parley, Technology, Economics of the FIFA World Cup, Food, PET, Adidas, Industrial waste, USD, Renewable energy

FENC integrated multiple resources and environmentally friendly products from FENC vertical chain, developing high performance functional and sustainable fabrics for international brands.

Key Points: 
  • FENC integrated multiple resources and environmentally friendly products from FENC vertical chain, developing high performance functional and sustainable fabrics for international brands.
  • Not only satisfy the everyday wear of end consumers, FENC also had been a major supplier at global sporting events.
  • The fabrics scraps and used clothes with go through a process of sorting, shredding, melting, pelletizing and spinning.
  • FENC TOPGREEN Bio3 PET utilizes LanzaTech CCU technology that transforms industrial waste gas into low carbon ethylene glycol (EG), which then turn into brand new polyester.

Global Personal 3D Printers Market Report 2022-2027: Surging Demand for 3D Printing in Dental Industry Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 31, 2022
Technology, Hardware, Consumer Electronics, Electron-beam additive manufacturing, Process, Market development, Observation, FDM, Selective laser melting, Porter's five forces analysis, Fiberglass sheet laminating, USD, Global, SLS, Selective laser sintering, Fashion, Manufacturing, Others, DMLS, Ansoff Matrix, Stereolithography, Investment, Geography, Component, Inkjet printing, SWOT, Digital Light Processing, CAGR, Material extrusion-based additive manufacturing, Risk, EBM, COVID-19, Slic3r, Growth, Industry, 3D printing, Retail, Technology, Application, Software, Filament, Photography, Powder, Architecture, Form

The Global Personal 3D Printers Market is segmented based on Components, Type, Technology, Form, Manufacturing Process, Application, and Geography.

Key Points: 
  • The Global Personal 3D Printers Market is segmented based on Components, Type, Technology, Form, Manufacturing Process, Application, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Personal 3D Printers Market.
  • The analyst analyses the Global Personal 3D Printers Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Personal 3D Printers Market.

Europe Polypropylene In 3D Printing Market Poised to Hit $4.08 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022
Electronic Design Automation, Chemicals, Plastics, Automotive Manufacturing, Technology, Manufacturing, Hardware, National Research Council Canada, NRC, Country, Industry, Covestro, Final good, National Research Council, 3D, Form, Technology, Growth, 3D printing processes, Printing, Artificial intelligence, BASF, BCT, Weight, Scope, TPU, PBT, 3D Hubs, DED, Process, Polymer, Filament, Partnership, ILT, CAGR, Volkswagen Group, Organization, SE, Automotive industry, BASF SE, Thermoplastic polyurethane, McGill University, Defense, USD, Adoption, 3D printing, Thermoplastic, Powder

The Europe polypropylene in 3D printing market size is expected to reach USD 4,084.44 million by 2030.

Key Points: 
  • The Europe polypropylene in 3D printing market size is expected to reach USD 4,084.44 million by 2030.
  • 3D hubs, 3D Ceram, 3D Prod, and 3D Ceram SAS are some of the companies that integrate 3D printing, creating opportunities for 3D printed polypropylene.
  • End-use industry players in Europe are investing heavily in developing 3D printing technologies which can fuel the market for polypropylene in 3D printing.
  • Chapter 3 Europe Polypropylene in 3D Printing Market Variables, Trends, and Scope
    Chapter 4 Europe Polypropylene in 3D Printing Market: Form Estimates & Trend Analysis
    Chapter 5 Europe Polypropylene in 3D Printing Market: End-use Estimates & Analysis
    Chapter 6 Polypropylene in 3D Printing Market: Regional Estimates & Trend Analysis

Global Epoxy Composite Markets, 2022-2027 - Increasing Need for Material with High Mechanical Strength, Lightweight, and Resistance Against Corrosion - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 21, 2022
Chemicals, Plastics, Manufacturing, Carbon, Transfer, Glass fiber, SWOT, Investment, Others, Defense, COVID-19, Market development, Process, Industry, Electricity, Transport, Risk, Carbon-fiber-reinforced polymers, ATL, USD, Ansoff Matrix, Geography, Electrical engineering, CAGR, Sporting Goods, Filament, Manufacturing, Emotion, Competitive analysis, Marine, Impact, Growth, Automotive industry, Corrosion, Retail, Risk management, Lightweight

Market dynamics are forces that impact the prices and behaviors of the Global Epoxy Composite Market stakeholders.

Key Points: 
  • Market dynamics are forces that impact the prices and behaviors of the Global Epoxy Composite Market stakeholders.
  • These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service.
  • The report presents a detailed Ansoff matrix analysis for the Global Epoxy Composite Market.
  • Increasing Need for Material with High Mechanical Strength, Lightweight, and Resistance Against Corrosion
    By Fiber Type, the market is classified into Glass Fiber, Carbon Fiber, and Other Fibers.

Filament Health Announces First Dosing in Groundbreaking FDA-Approved Psilocin Clinical Trial

Retrieved on: 
Thursday, July 7, 2022
Science, Biotechnology, Research, Pharmaceutical, Alternative Medicine, Health, FDA, Clinical Trials, FDA, OTCQB, CEO, FH, Research, NEO, Health, Filament, Psilocybin, Food, Clinical trial, University, Principal investigator, Food and Drug Administration, Pharmaceutical industry

Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (Filament), a clinical-stage natural psychedelic drug development company, today announced the beginning of dosing in the first United States Food and Drug Administration (FDA)-approved clinical trial studying the effects of naturally derived psychedelic drug candidates.

Key Points: 
  • Filament Health Corp. ( OTCQB:FLHLF ) ( NEO:FH ) ( FSE:7QS ) (Filament), a clinical-stage natural psychedelic drug development company, today announced the beginning of dosing in the first United States Food and Drug Administration (FDA)-approved clinical trial studying the effects of naturally derived psychedelic drug candidates.
  • The trial is investigating three of Filaments proprietary botanical drug candidates, naturally extracted and stabilized forms of the psychedelic compounds found in certain mushrooms.
  • The trial objective is to compare the physiological and psychological effects of orally administered psilocybin, orally administered psilocin, and sublingually administered psilocin among healthy adults over a series of exposures.
  • This is the first time psilocin in either a natural or synthetic form has ever been administered in an FDA-approved clinical trial.

Global Industry Analysts Predicts the World Aviation Blockchain Market to Reach $1.4 Billion by 2026

Retrieved on: 
Monday, June 27, 2022
Aeron, Insolar, Transaction, Research, Microsoft, Airport, Supply chain management, Intelligence, Marketing, COVID-19, Aviation, Geography, Growth, Forecasting, Public, GIA, Internet, SAN, CAGR, IBM, Players, Pet, Infosys, Filament, Others

SAN FRANCISCO, June 27, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Aviation Blockchain - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, June 27, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Aviation Blockchain - Global Market Trajectory & Analytics" .
  • Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more.
  • Preview Registry
    Amid the COVID-19 crisis, the global market for Aviation Blockchain estimated at US$497.4 Million, is projected to reach a revised size of US$1.4 Billion by 2026, growing at a CAGR of 18.8% over the analysis period.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Psyence Group Corporate Update

Retrieved on: 
Thursday, June 2, 2022
Chief of Army Staff (Pakistan), Psychotherapy, OTCQB, Company, Contract research organization, Doctor of Philosophy, Radio Cooperativa, Group, Clerkenwell, Sale, Neurology, Medical director, Wellness, Pharmacy, Drug development, CSE, Marketing, Canadian Securities Exchange, MBA, Depression, Filament, Palliative care, Potential, Coffee, Quality assurance, Development, Health Canada, CAD, CRO, United Kingdom, Investment banking, Mycology, Anxiety, Mental health, Partner, Medicine, Anxiety disorder, Psilocybin, Psychological trauma, Exercise, Science, Research, Proceeds of Crime Act 2002, Nature, API, Therapy, FDA, Growth, GLOBE, Risk, Research and development, Clinical trial, Crime, Drink, Person, Safety, Pharmaceutical industry, Medical device, Oil, MD, Psyence, Angus Goodleaf

TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function. The Psyence Group develops and provides innovative, safe, and effective psychedelic and nature-centered solutions for mental health and palliative care.

Key Points: 
  • Partnership with CRO Clerkenwell Health to design and deliver Psyences UK clinical trial progressing; exclusive licensing agreement with Filament Health
    Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization for Psyence
    Exploring capital market initiatives in UK, hires Investment Bank
    TORONTO, June 02, 2022 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (Psyence or the Company) is pleased to provide the following corporate update on its three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function.
  • The Psyence Group develops and provides innovative, safe, and effective psychedelic and nature-centered solutions for mental health and palliative care.
  • In addition, Psyence appointed Dr. Clive Ward-Able as Medical Director, Head of Research & Development and Early Commercialization for Psyence in December 2021.
  • Our key divisions, Psyence Production, Psyence Therapeutics and Psyence Function, anchor an international collaboration, with operations in Canada, the United Kingdom, Southern Africa, and a presence in the United States and Australia.

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Retrieved on: 
Tuesday, May 31, 2022
Foot, Filament, GMP, Health, Goal, FH, EU, Research, CSE, NEO, Safety, Drug development, FRA, GLOBE, Pharmaceutical industry, Fungiculture

Our supply agreement with Filament Health is an excellent fit for both parties, said Optimi CEO Bill Ciprick.

Key Points: 
  • Our supply agreement with Filament Health is an excellent fit for both parties, said Optimi CEO Bill Ciprick.
  • Under the agreement, both companies have agreed to a one-year term which would allow Filament to place orders for whole, dried fruiting body mushrooms on a case-by-case basis.
  • We are pleased to partner with Optimi as we build out our own supply chain and explore external suppliers, added Filament Health CEO and Co-Founder Benjamin Lightburn.
  • Optimi Health Corp. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.

Filament Health to Webcast Live at VirtualInvestorConferences.com April 28th

Retrieved on: 
Monday, April 25, 2022
Patent, Drug development, CEO, Health, USPTO, Entrepreneurship, GLOBE, PIND, The Division, Psychiatry, Intellectual property, United States Patent and Trademark Office, OTCQB, Division, VIC, FH, FDA, Filament, NEO, Security (finance), Pharmaceutical industry

VANCOUVER, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Filament Health (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical-stage natural psychedelic drug development company, today announcedthat Benjamin Lightburn, CEO and Co-Founder, will present live at VirtualInvestorConferences.com on April 28th, 2022.

Key Points: 
  • VANCOUVER, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Filament Health (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical-stage natural psychedelic drug development company, today announcedthat Benjamin Lightburn, CEO and Co-Founder, will present live at VirtualInvestorConferences.com on April 28th, 2022.
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.